Capricor Therapeutics' StealthX Vaccine Chosen for Project NextGen

Capricor Therapeutics made an exciting announcement today, revealing that its groundbreaking StealthX exosome-based multivalent vaccine has been selected to be part of Project NextGen. This news caused Capricor Therapeutics shares to surge 7% to $4.42.

Project NextGen, initiated by the U.S. Health and Human Services Department, aims to propel a pipeline of innovative vaccines that offer broader and more durable protection against SARS-CoV-2, the virus responsible for Covid-19. This selection is a significant achievement for Capricor Therapeutics and highlights the potential of their StealthX vaccine.

The National Institute of Allergy and Infectious Diseases (NIAID), a branch of the National Institutes of Health, will be conducting a Phase 1 clinical study on Capricor's StealthX vaccine as part of Project NextGen. However, it is worth noting that this study is subject to regulatory approval. The NIAID's Division of Microbiology and Infectious Diseases will oversee the study, ensuring rigorous scientific evaluation.

Capricor's StealthX vaccine stands out due to its proprietary design, utilizing exosomes engineered to express spike or nucleocapsid proteins on their surface. Promising preclinical results from murine and rabbit models have demonstrated the vaccine's ability to elicit a robust antibody response, generate potent neutralizing antibodies, stimulate a strong T-cell response, and maintain a favorable safety profile.

As Capricor Therapeutics continues to make strides in the development of their innovative StealthX vaccine, we eagerly anticipate further updates on its progress.